Understanding the epidemiology and perceived efficacy of cannabis use in patients with chronic musculoskeletal pain.

IF 4.1 Q1 PHARMACOLOGY & PHARMACY Journal of cannabis research Pub Date : 2024-07-03 DOI:10.1186/s42238-024-00231-1
Timothy Leroux, Prabjit Ajrawat, Kala Sundararajan, Naomi Maldonado-Rodriguez, Bheeshma Ravi, Rajiv Gandhi, Raja Rampersaud, Christian Veillette, Nizar Mahomed, Hance Clarke
{"title":"Understanding the epidemiology and perceived efficacy of cannabis use in patients with chronic musculoskeletal pain.","authors":"Timothy Leroux, Prabjit Ajrawat, Kala Sundararajan, Naomi Maldonado-Rodriguez, Bheeshma Ravi, Rajiv Gandhi, Raja Rampersaud, Christian Veillette, Nizar Mahomed, Hance Clarke","doi":"10.1186/s42238-024-00231-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The belief that cannabis has analgesic and anti-inflammatory properties continues to attract patients with chronic musculoskeletal (MSK) pain towards its use. However, the role that cannabis will play in the management of chronic MSK pain remains to be determined. This study examined 1) the rate, patterns of use, and self-reported efficacy of cannabis use among patients with chronic MSK pain and 2) the interest and potential barriers to cannabis use among patients with chronic MSK pain not currently using cannabis.</p><p><strong>Methods: </strong>Self-reported cannabis use and perceived efficacy were prospectively collected from chronic MSK pain patients presenting to the Orthopaedic Clinic at the University Health Network, Toronto, Canada. The primary dependent variable was current or past use of cannabis to manage chronic MSK pain; bivariate and multivariable logistic regression were used to identify patient characteristics independently associated with this outcome. Secondary outcomes were summarized descriptively, including self-perceived efficacy among cannabis users, and interest as well as barriers to cannabis use among cannabis non-users.</p><p><strong>Results: </strong>The sample included 629 patients presenting with chronic MSK pain (mean age: 56±15.7 years; 56% female). Overall, 144 (23%) reported past or present cannabis use to manage their MSK pain, with 63.7% perceiving cannabis as very or somewhat effective and 26.6% considering it as slightly effective. The strongest predictor of cannabis use in this study population was a history of recreational cannabis use (OR 12.7, p<0.001). Among cannabis non-users (N=489), 65% expressed interest in using cannabis to manage their chronic MSK pain, but common barriers to use included lack of knowledge regarding access, use and evidence, and stigma.</p><p><strong>Conclusions: </strong>One in five patients presenting to an orthopaedic surgeon with chronic MSK pain are using or have used cannabis with the specific intent to manage their pain, and most report it to be effective. Among non-users, two-thirds reported an interest in using cannabis to manage their MSK pain, but common barriers to use existed. Future double-blind placebo-controlled trials are required to understand if this reported efficacy is accurate, and what role, if any, cannabis may play in the management of chronic MSK pain.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"6 1","pages":"28"},"PeriodicalIF":4.1000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220958/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cannabis research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42238-024-00231-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The belief that cannabis has analgesic and anti-inflammatory properties continues to attract patients with chronic musculoskeletal (MSK) pain towards its use. However, the role that cannabis will play in the management of chronic MSK pain remains to be determined. This study examined 1) the rate, patterns of use, and self-reported efficacy of cannabis use among patients with chronic MSK pain and 2) the interest and potential barriers to cannabis use among patients with chronic MSK pain not currently using cannabis.

Methods: Self-reported cannabis use and perceived efficacy were prospectively collected from chronic MSK pain patients presenting to the Orthopaedic Clinic at the University Health Network, Toronto, Canada. The primary dependent variable was current or past use of cannabis to manage chronic MSK pain; bivariate and multivariable logistic regression were used to identify patient characteristics independently associated with this outcome. Secondary outcomes were summarized descriptively, including self-perceived efficacy among cannabis users, and interest as well as barriers to cannabis use among cannabis non-users.

Results: The sample included 629 patients presenting with chronic MSK pain (mean age: 56±15.7 years; 56% female). Overall, 144 (23%) reported past or present cannabis use to manage their MSK pain, with 63.7% perceiving cannabis as very or somewhat effective and 26.6% considering it as slightly effective. The strongest predictor of cannabis use in this study population was a history of recreational cannabis use (OR 12.7, p<0.001). Among cannabis non-users (N=489), 65% expressed interest in using cannabis to manage their chronic MSK pain, but common barriers to use included lack of knowledge regarding access, use and evidence, and stigma.

Conclusions: One in five patients presenting to an orthopaedic surgeon with chronic MSK pain are using or have used cannabis with the specific intent to manage their pain, and most report it to be effective. Among non-users, two-thirds reported an interest in using cannabis to manage their MSK pain, but common barriers to use existed. Future double-blind placebo-controlled trials are required to understand if this reported efficacy is accurate, and what role, if any, cannabis may play in the management of chronic MSK pain.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解慢性肌肉骨骼疼痛患者使用大麻的流行病学和感知疗效。
背景:人们认为大麻具有镇痛和抗炎特性,这继续吸引着慢性肌肉骨骼(MSK)疼痛患者使用大麻。然而,大麻在慢性肌肉骨骼疼痛治疗中的作用仍有待确定。本研究调查了:1)慢性肌肉骨骼疼痛患者使用大麻的比例、使用模式和自我报告的疗效;2)目前未使用大麻的慢性肌肉骨骼疼痛患者使用大麻的兴趣和潜在障碍:前瞻性地收集了前往加拿大多伦多大学健康网络骨科诊所就诊的慢性 MSK 疼痛患者的自我报告大麻使用情况和感知疗效。主要因变量是当前或过去使用大麻来控制慢性 MSK 疼痛;使用二元和多元逻辑回归来确定与这一结果独立相关的患者特征。对次要结果进行了描述性总结,包括大麻使用者的自我感觉疗效,以及非大麻使用者使用大麻的兴趣和障碍:样本包括 629 名慢性 MSK 疼痛患者(平均年龄:56±15.7 岁;56% 为女性)。总体而言,有 144 人(23%)报告过去或现在使用大麻来控制其 MSK 疼痛,其中 63.7% 的人认为大麻非常有效或有点有效,26.6% 的人认为大麻稍微有效。在本研究人群中,使用大麻的最强预测因素是娱乐性大麻使用史(OR 12.7,p 结论:每五名向骨科外科医生求诊的慢性 MSK 疼痛患者中就有一人正在使用或曾经使用过大麻,其特定目的是为了控制疼痛,而且大多数人认为大麻是有效的。在未使用大麻的患者中,有三分之二的人表示有兴趣使用大麻来控制他们的 MSK 疼痛,但在使用过程中普遍存在障碍。未来需要进行双盲安慰剂对照试验,以了解所报告的疗效是否准确,以及大麻在治疗慢性 MSK 疼痛方面可能发挥的作用(如果有的话)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
期刊最新文献
Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol. Association between cannabis use and physical activity in the United States based on legalization and health status. Cannabis-related information sources among US residents: A probability-weighted nationally representative survey. Attitudes toward driving after cannabis use: a systematic review. Changes in health-related quality of life over the first three months of medical marijuana use.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1